// App-Quantinova.ai

5042 : NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Sebastien J. Hotte

Principal Investigators

  • Anthony Michael Joshua

  • Ankineedu Saranya Kakumanu

  • Scott A. North

  • Christian K. Kollmannsberger

  • Anna Tinker

  • Deepu Mirchandani

  • Aurelie Tassignon

  • Diana Felice Hausman

  • Alison L Allan

  • Kim N. Chi

  • Vikaash Kumar

  • Susan Ellard

  • Richard William Gregg

  • Robyn Jane Macfarlane

  • Eric Winquist

  • Vamsee Torri

  • Joseph D. Ruether

  • Naveen S. Basappa

Medical Centers

  • Cancer Centre for Southern Interior, Kelowna, BC, Canada

  • Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Vancouver Cancer Centre, British Columbia Cancer Agency, Vancouver, BC, Canada

  • London Regional Cancer Program, London Health Sciences Centre, London, ON, Canada

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Oncothyreon, Seattle, WA

  • Tom Baker Cancer Center, Calgary, AB, Canada

  • London Health Sciences Center, London, ON, Canada

  • Cancer Centre Of Southeastern Ontario, Kingston, ON, Canada

  • Cancer Centre Of Southeastern Ontario, Kingston, ON, Canada

  • Queen's University, Department of Medicine, Kingston, ON, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Docetaxel

  • PX866

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01331083

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved